Gianni Sava

Prof. Gianni SAVA
LIST OF SCIENTIFIC PUBBLICATIONS (1975-2018)
1) Giraldi T, Nisi C, Sava G. Investigation on the oxidative N-demethylation of aryltriazenes in vitro. Biochem. Pharmacol., 24: 1793-1797 (1975). IF(1999)= 2.755
2) Giraldi T, Baldini L, Sava G. Effects of N-diazoacetyl-glycine amide on the pool of 5-phosphoribosyl-1-pyrophosphate in Ehrlich ascites tumor cells. Biochem. Pharmacol., 25: 725 (1976). IF(1999)= 2.755
3) Giraldi T, Nisi C, Sava G. Observations of the oxidative N-demethylation of 4-(3,3-dimethyl-1-triazeno)-imidazole-5-carboxamide (DTIC, NSC-45388). Pharmacol. Res. Commun., 8: 25-29 (1976). IF(1999)= 0.715
4) Giraldi T, Nisi C, Sava G. Antimetastatic effects of N-diazoacetylglycine derivatives in C57BL mice. J. Natl. Cancer Inst., 58: 1129-1130 (1977). IF(1999)= 12.945
5) Giraldi T, Nisi C, Sava G. Lysosomal enzyme inhibitors and antimetastatic activity in the mouse. Eur. J. Cancer, 13: 1321-1323 (1977). IF(1999)= 2.537
6) Giraldi T, Sava G, Bertoli G, Mestroni G, Zassinovich G. Antitumor action of two rhodium and ruthenium complexes in comparison with cis-diamminedichloro-platinum(II). Cancer Res., 37: 2662-2666 (1977). IF(1999)= 8.614
7) Giraldi T, Kopitar M, Sava G. Antimetastatic effects of a leukocyte intracellular inhibitor of neutral proteinases. Cancer Res., 37: 3834-3835 (1977). IF(1999)= 8.614
8) Giraldi T, Sava G, Mestroni G, Zassinovich G, Stolfa D. Antitumor action of rhodium(I) and iridium(I) complexes. Chem. Biol. Interactions, 22: 231-238 (1978). IF(1999)= 1.887
9) Sava G, Bertoli G, Giraldi T. Cardiovascular effects of sodium sulphide in the anesthesized rat. Riv. Farmacol. Ter., IX: 105-109 (1978).
10) Sava G, Lunazzi G, Callerio C, Giraldi T. Growth of Ehrlich ascites carcinoma and lysozymuria in mice after administration of heparin, lysozyme and their complex. Riv. Farmacol. Ter., IX: 159-165 (1978).
11) Sava G, Giraldi T, Lassiani L, Nisi C. Mechanism of the antimetastatic action of dimethyltriazenes. Cancer Treat. Rep., 63: 93-98 (1979). IF (dal 1985 confluito in JNCI)
12) Sentiurc M, Schara M, Nemec M, Cotic V, Pecar S, Sava G, Giraldi T. Leukemic L1210 cell membrane modifications by cholesterol treatment. Studia Biophys., 75: 13-24 (1979).
13) Giraldi T, Sava G, Nisi C. Mechanism of the antimetastatic action of N- diazoacetylglycinamide in mice bearing Lewis lung carcinoma. Eur. J. Cancer., 16: 87-92 (1980). IF(1999)= 2.537
14) Giraldi T, Guarino AM, Nisi C, Sava G. Antitumor and antimetastatic effects of benzenoid triazenes in mice bearing Lewis lung carcinoma. Pharmacol. Res. Commun., 12: 1-11 (1980). IF(1999)= 0.715
15) Giraldi T, Sava G, Kopitar M, Brzin J, Turk V. Neutral proteinase inhibitors and antimetastatic effects in mice. Eur. J. Cancer, 16: 449-454 (1980). IF(1999)= 2.537
16) Sava G, Bertoli G, Giraldi T. Effects of sodium sulfide on bile flow in the anesthetized rat. Riv. Farmacol. Ter., XI: 15-20 (1980).
17) Lassiani L, Nisi C, Sigon F, Sava G, Giraldi T. Synthesis of 1-aryl-3-formyl-3-methyltriazenes, potential metabolites of 1-aryl-3,3-dimethyltriazenes. J. Pharm. Sci., 69: 1098-1099 (1980). IF(1999)= 2.270
18) Giraldi T, Sava G, Cuman R, Nisi C, Lassiani L. Prophylactic antimetastatic agents: dimethyltriazenes, N-diazoacetylglycine derivatives and other neutral proteinase inhibitors. In:Metastasis, Clinical and Experimental Aspects» (K Hellmann, P Hilgard and S Eccles, Eds) pp. 436-440, Martinus Nijhoff Publishers, The Hague (1980).
19) Cuman R, Giraldi T, Lassiani L, Nisi C, Sava G. Mechanism of the antileukemic action of dimethyltriazenes in mice. Br. J. Pharmacol., 72: 107P (1981). IF(1999)= 3.722
20) Giraldi T, Sava G. Selective antimetastatic drugs (review). Anticancer Res., 1: 163-174 (1981). IF(1999)= 1.375
21) Giraldi T, Sava G. Malignancy and tumor proteinases: effects of proteinase inhibitors. In: Proteinases and Their Inhibitors. Structure, Function and Applied Aspects (V Turk, Lj Vitale, Eds) pp. 45-56, Pergamon Press, Oxford (1981).
22) Sava G, Giraldi T. Effects of sodium sulfide on the bile flow in the anesthetized guinea pig. Riv. Farmacol. Ter., XII: 27-34 (1981).
23) Giraldi T, Sava G, Cuman R, Nisi C, Lassiani L. Selectivity of the antimetastatic and cytotoxic effects of p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt, (±)1,2-di(3,5-dioxopiperazin-1-yl)propane and cyclophosphamide in mice bearing Lewis lung carcinoma. Cancer Res., 41: 2524-2528 (1981). IF(1999)= 8.614
24) Fioretti MC, Nardelli B, Bianchi R, Nisi C, Sava G. Antigenic changes of a murine lymphoma by in vivo treatment with triazene derivatives. Cancer Immunol. Immunother., 11: 283-286 (1981). IF(1999)= 2.293
25) Sava G, Giraldi T, Baldini L, Nisi C. Azione antimetastatica di N-diazoacetylderivati della glicina. In: Apporto della ricerca di base al controllo della crescita neoplastica, pp. 715-719, Idelson, Napoli (1981).
26) Giraldi T, Sava G, Lassiani L, Nisi C. Effetti di farmaci antitumorali sulla crescita e formazione di metastasi di tumori sperimentali. In: Apporto della ricerca di base al controllo della crescita neoplastica, pp. 705-714, Idelson, Napoli (1981).
27) Giraldi T, Sava G, Brzin J, Kopitar M, Suhar A, Turk V. Inibitori di proteinasi ed effetti antimetastatici in topi portatori del Lewis lung carcinoma. In: Apporto della ricerca di base al controllo della crescita neoplastica, pp. 721-726, Idelson, Napoli (1981).
28) Giraldi T, Sava G, Kopitar M, Brzin J, Suhar A, Turk V. Antimetastatic effects and tumor proteinase inhibition by spleen intracellular inhibitors of neutral proteinases. Eur. J. Cancer Clin. Oncol., 17: 1301-1306 (1981). IF(1999)= 2.537
29) Sava G, Giraldi T, Baldini L. Antitumor activity of N-diazoacetyl derivatives of glycine and phenylalanine against P388 leukemia and B16 melanoma in mice. Cancer Treat. Rep., 66: 179-181 (1982). IF(dal 1985 confluito in JNCI)
30) Sava G, Giraldi T, Nisi C, Bertoli G. Prophylactic antimetastatic treatment with aryldimethyltriazenes as adjuvants to surgical tumor removal in mice bearing Lewis lung carcinoma. Cancer Treat. Rep., 66: 115-120 (1982). IF(dal 1985 confluito in JNCI)
31) Kopitar M, Drobnik-Kosoro M, Babnik J, Brzin J, Turk V, Korbelik M, Batista U, Svetina S, Skrk J, Giraldi T, Sava G. Biochemical and biological characteristics of leukocyte proteinase inhibitors. In: Biochemistry and function of phagocytes (F Rossi, P Patriarca, Eds) pp. 235-245, Plenum Publishing Corporation (1982).
32) Giraldi T, Sava G, Lassiani L, Nisi C. Selectivity of the mechanism of action of antimetastatic drugs. In: Current Chemotherapy and Immunotherapy - proceedings of the 12th International Congress of Chemotherapy (P Periti, G Gialdroni-Grassi, Eds) pp. 1276-1278, American Society for Microbiology (1982).
33) Sava G, Giraldi T, Cuman R, Lassiani L, Nisi C. Mechanism of the antileukemic activity of dimethyltriazenes in mice. In: Current Chemotherapy and Immunotherapy - proceedings of the 12th International Congress of Chemotherapy (P Periti, G Gialdroni-Grassi, Eds) pp. 1329-1331, American Society for Microbiology (1982).
34) Kopitar M, Brzin J, Drobnik-Kosorok M, Babnik J, Locnikar P, Turk V, Giraldi T, Sava G. Some further characteristics of endogenous proteinase inhibitors. Acta Biol. Med. Germ., 41: 75-82 (1982).
35) Sava G, Giraldi T, Lassiani L, Nisi C. Metabolism and mechanism of the antileukemic action of isomeric aryldimethyltriazenes. Cancer Treat. Rep., 68: 1751-1755 (1982). IF(dal 1985 confluito in JNCI)
36) Giraldi T, Sava G, Kopitar M, Suhar A, Turk V, Baici A. Metodologic problems encountered in the assay of proteinases in Lewis lung carcinoma, a mouse metastasizing tumor. Tumori, 68: 381-387 (1982). IF(1999)= 0.569
37) Sava G, Giraldi T, Lassiani L, Nisi C, Farmer PB. Mechanism of the antileukemic effects of 1-p-carboxamidophenyl-3,3-dimethyltriazene and its in vitro metabolites. Biochem. Pharmacol., 31: 3629-3634 (1982). IF(1999)= 2.755
38) Sava G, Giraldi T. Antitumor effects of GANU and other nitrosourea derivatives against transplantable leukemias and solid tumors in mice. Cancer Chemother. Pharmacol., 10: 167-169 (1983). IF(1999)= 1.689
39) Sava G, Giraldi T, Mestroni G, Zassinovich G. Antitumor effects of rhodium(I), iridium(I) and ruthenium(II) complexes in comparison with cis-dichloro-diamminoplatinum(II) in mice bearing Lewis lung carcinoma. Chem. Biol. Interactions, 45: 1-6 (1983). IF(1999)= 1.887
40) Sava G, Giraldi T, Tomasic J, Hrsak I. Immunotherapy of Lewis lung carcinoma with hydrosoluble peptidoglycan monomer (PGM). Cancer Immunol. Immunother., 15: 84-86 (1983). IF(1999)= 2.293
41) Sava G, Giraldi T, Lassiani L, Dogani R. Effects of isomeric aryldimethyl-triazenes on Lewis lung carcinoma growth and metastases in mice. Chem. Biol. Interactions, 46: 131-136 (1983). IF(1999)= 1.887
42) Lassiani L, Nisi C, Sava G, Giraldi T. Synthesis and antitumor activity of N-(3,3-dimethyl-1-triazeno)benzoylaminoacids. Eur. J. Med. Chem-chim. Ther., 18: 401-403 (1983). IF(1999)= 1.074
43) Sentiurc M, Schara M, Nemec M, Sava G, Giraldi T. Influence of antimetastatic drugs on L-1210 cell membranes. Farmacevtski Vestnik, 34: 229-238 (1983).
44) Giraldi T, Sava G, Cherubino R, Lassiani L, Bottiroli G, Mazzini G. Metastasis: mitostatic drugs. In: The Control of Tumour Growth and Its Biological Bases (W Davis, C Maltoni, St Tanneberger, Eds) pp. 55-62, Akademie-Verlag, Berlin (1983).
45) Sava G, Giraldi T, Lassiani L, Nisi C. Mechanism of the antileukemic action of DTIC and its benzenoid analog DM-COOK in mice. In: The Control of Tumour Growth and Its Biological Bases (W Davis, C Maltoni, St Tanneberger, Eds) pp. 309-312, Akademie-Verlag (1983).
46) Bartoli-Klugmann F, Decorti G, Perissin L, Zorzet S, Sava G, Giraldi T. Effects of antineoplastic drugs on the proteolytic activity of murine metastasizing tumors. Chemioterapia, II: 363-367 (1983).
47) Giraldi T, Sava G, Cherubino R. Selective antimetastatic action of p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt (DM-COOK). In: Proceedings of the 13th International Congress of Chemotherapy (KH Spitzy, K Karrer, Eds) pp, TOM 16, Verlag H Hegermann, Vienna (1983).
48) Sava G, Giraldi T, Bartoli-Klugmann F, Decorti G, Perissin L. Antileukemic action of p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt (DM-COOK). In: Proceedings of the 13th International Congress of Chemotherapy (KH Spitzy, K Karrer, Eds) pp. 69-72, TOM 16, Verlag H Hegermann, Vienna (1983).
49) Nardelli B, Contessa AR, Puccetti P, Sava G, Nisi C, Fioretti MC. Chemical xenogenization of lymphoma cells treated in vitro with triazene derivatives. In: Proceedings of the 13th International Congress of Chemotherapy (KH Spitzy, K Karrer, Eds) pp. 84-86, TOM 17, Verlag H Hegermann, Vienna (1983).
50) Sava G, Giraldi T, Bartoli-Klugmann F, Decorti G, Mallardi F. Effects of p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt on leukemic infiltration of brain and liver in mice bearing P388 leukemia. Eur. J. Cancer Clin. Oncol., 20: 287-289 (1984). IF(1999)= 2.537
51) Nardelli B, Contessa AR, Romani L, Sava G, Nisi C, Fioretti MC. Immuno¬genic changes of murine lymphoma cells following in vitro treatment with aryl-triazene derivatives. Cancer Immunol. Immunother., 16: 157-161 (1984). IF(1999)= 2.293
52) Sava G, Giraldi T, Lassiani L, Nisi C. Antimetastatic action and hematological toxicity of p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt and 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide used as prophylactic adjuvants to surgical tumor removal in mice bearing B16 melanoma. Cancer Res., 44: 64-68 (1984). IF(1999)= 8.614
53) Kopitar M, Babnik J, Brzin J, Drobnik-Kosorok M, Turk V, Rozman B, Giraldi T, Sava G. The properties and physiological role of endogenous inhibitors of cysteine and serine proteinases. Symposia Biologica Hungarica, 25: 219-232 (1984).
54) Sava G, Zorzet S, Giraldi T, Mestroni G, Zassinovich G. Antineoplastic activity and toxicity of an organometallic complex of ruthenium(II) in comparison with cis-PDD in mice bearing solid malignant neoplasms. Eur. J. Cancer Clin. Oncol., 20: 841-847 (1984). IF(1999)= 2.537
55) Giraldi T, Sava G, Mitri E, Cherubino R. Hemostasis and mechanism of action of selective antimetastatic drugs in mice bearing Lewis lung carcinoma. Eur. J. Cancer Clin. Oncol., 20: 961-966 (1984). IF(1999)= 2.537
56) Lassiani L, Nisi C, Giraldi T, Sava G, Cuman R. Selective antimetastatic triazenes: a quantitative approach. Quant. Struct-Act-Relat., 3: 59-62 (1984). IF(1999)= 1.803
57) Giraldi T, Sava G, Cherubino R, Bottiroli G, Mazzini G. Effects of DTIC, DM-COOK and ICRF-159 on the number of circulating Lewis lung carcinoma cells detected by flow cytometry. Clin. Expl. Metastasis, 2: 151-159 (1984). IF(1999)= 2.000
58) Nardelli B, Puccetti P, Romani L, Sava G, Bonmassar E, Fioretti MC. Chemical xenogenization of murine lymphoma cells with triazene derivatives: immunotox-icological studies. Cancer Immunol. Immunother., 17: 213-217 (1984). IF(1999)= 2.293
59) Giraldi T, Sava G, Perissin L, Zorzet S. Primary tumor growth and formation of spontaneous lung metastases in mice bearing Lewis lung carcinoma treated with proteinase inhibitors. Anticancer Res., 4: 221-224 (1984). IF(1999)= 1.375
60) Sava G, Giraldi T, Zupi G, Sacchi A. Effects of antimetastatic dimethyltriazenes in mice bearing Lewis lung carcinoma lines with different metastatic potential. Invasion Metastasis, 4: 171-178 (1984). IF(1999)= 1.324
61) Sava G, Tomasic J, Hrsak I. Antitumor and antimetastatic activity of the immunoadjuvant peptidoglycan monomer PGM in mice bearing MCa mammary carcinoma. Cancer Immunol. Immunother., 18: 49-53 (1984). IF(1999)= 2.293
62) Sava G, Giraldi T, Perissin L, Zorzet S, Mallardi F, Grill V. Infiltra-tion in liver and brain by tumor cells in leukemic mice: prevention by dimethyltriazenes and cyclophosphamide. Tumori, 70: 477-483 (1984). IF(1999)= 0.569
63) Sava G, Perissin L, Zorzet S, Tomasic J, Hrsak I. Antitumor properties of the immunoadjuvant peptidoglycan monomer PGM. J. Pharmacol., 15: 476-477 (1984).
64) Sava G, Perissin L, Giraldi T, Bosatra A. Effetti del sodio solfuro sulla muscolatura liscia di trachea di cavia in vitro. Riv. Farmacol. Ter., XV: 37-43 (1984).
65) Sava G, Perissin L, Lassiani L, Zabucchi G. Antiinflammatory action of hydrosoluble dimethyltriazenes on the carrageenin-induced edema in guinea pigs. Chem. Biol. Interactions, 53: 37-43 (1985). IF(1999)= 1.887
66) Sava G, Perissin L, Zorzet S, Tomasic J. Effects of dimethyltriazenes combined with surgery and non-specific immunotherapy in mice bearin Lewis lung carcinoma lines. Anticancer Res., 5: 301-306 (1985). IF(1999)= 1.375
67) Sava G, Zorzet S, Mestroni G, Zassinovich G. Antineoplastic Activity of planar Rhodium(I) complexes in mice bearing Lewis lung carcinoma and P388 leukemia. Anticancer Res., 5: 249-252 (1985). IF(1999)= 1.375
68) Giraldi T, Sava G, Perissin L, Zorzet S. Proteinases and proteinase inhibition by cytotoxic and antimetastatic drugs in transplantable solid metastasizing tumors in mice. Anticancer Res., 5: 355-360 (1985). IF(1999)= 1.375
69) Nardelli B, Puccetti P, Sava G, Romani L, Contessa AR, Lassiani L, Fioretti MC. Importanza del farmaco-metabolismo epatico nella immunotossicità di triazeno-derivati. Therapeutika, 11: 268-270 (1985).
70) Sava G, Zorzet S, Perissin L. Therapeutic activity of ICRF-159 combined with surgery: effects of postsurgical treatment with cyclophosphamide in mice bearing Lewis lung carcinoma lines. Anticancer Res., 5: 511-516 (1985). IF(1999)= 1.375
71) Giraldi T, Sava G, Perissin L, Zorzet S, Decorti G, Steven FS. Tumor cell metastasis and surface neutral proteinase: effects of antimetastatic drugs. Invasion Metastasis, 5: 336-343 (1985). IF(1999)= 1.324
72) Giraldi T, Sava G, Perissin L, Decorti G. Prevention of leukemic spread in mice by antimetastatic agents. In: Treatment of Metastasis: Problems and Prospects (K Hellmann and SA Eccles, Eds), pp. 129-132, Taylor and Francis, London, (1985).
73) Giraldi T, Sava G, Perissin L, Zorzet S, Tamaro M, Dolzani L. DTIC e suoi derivati: farmaci citotossici o antimetastatici? Giorn. Ital. Chemiot., 32: 43-47 (1985).
74) Sava G, Zorzet S, Perissin L, Lassiani L, Tomasic J. Effects of postsurgical immunotherapy with PGM in mice bearing Lewis lung carcinoma treated with p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt. Meth. and Find. Exptl. Clin. Pharmacol., 7: 477-480 (1985). IF(1999)= 0.454
75) Giraldi T, Sava G, Perissin L, Zorzet S. Antimetastatic action of Dacarbazine and of its analog DM-COOK in mice bearing Malignant Metastasizing tumors. In: Recent Advances in Chemotherapy (Joji Ishigami Ed), pp. 533-534, University of Tokyo Press, (1985).
76) Sava G, Perissin L, Zorzet S, Callerio C. Antineoplastic effects of egg-white lysozyme in mice bearing solid metastasizing tumors. Anticancer Res., 6: 183-186 (1986). IF(1999)= 1.375
77) Tamaro M, Dolzani L, Monti-Bragadin C, Sava G. Mutagenic activity of the dacarbazine analog p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt in bacterial cells. Pharmacol. Res. Commun., 18: 491-501 (1986). IF(1999)= 0.715
78) Sava G, Giraldi T, Perissin L, Zorzet S, Decorti G. Effects of antimeta-static, antiinvasive and cytotoxic agents on the growth and spread of transplantable leukemias in mice. Clin. Expl. Metastasis, 5: 27-34 (1987). IF(1999)= 2.000
79) Sava G, Piccini P, Mestroni G, Zassinovich G, Bontempi A. Inhibitory effects of some organometallic complexes of rhodium(I) and iridium(I) on carrageenin paw edema in rats. In Vivo, 1: 27-30 (1987). IF(1999)= 0.794
80) Sava G, Zorzet S, Perissin L, Mestroni G, Zassinovich G, Bontempi A. Coordination metal complexes of Rh(I), Ir(I) and Ru(II): recent advances on antimetastatic activity on solid mouse tumors. Inorganica Chimica Acta, 137: 69-71 (1987). IF(1999)= 1.295
81) Sava G. Tumor animal models used for evaluating the antineoplastic activity of platinum coordination complexes. Inorganica Chimica Acta, 137: 39-44 (1987). IF(1999)= 1.295
82) Giraldi T, Sava G, Zorzet S, Perissin L, Piccini P. Activity and inhibition by cytotoxic antimetastatic drugs of cathepsin B-like cysteine proteinases in transplantable leukemias in mice. Anticancer Res., 7: 343-346 (1987). IF(1999)= 1.375
83) Zorzet S, Perissin L, Piccini P, Callerio C, Sava G. Antimetastatic action of egg-white lysozyme in mice bearing Lewis lung carcinoma. Folia Oncologica, 10 suppl. A: 219-224 (1987).
84) Sava G, Zorzet S, Perissin L, Piccini P, Mestroni G, Zassinovich G, Bontempi A. Antineoplastic action of coordination metal complexes of Rh(I) and Ir(I) in mice bearing Lewis lung carcinoma. Folia Oncologica, 10 suppl. A: 230-234 (1987).
85) Giraldi T, Sava G, Perissin L, Zorzet S. Role of host responses in the drug treatment of metastasis. In: Cancer Metastasis - Biological and Biochemical Mechanisms and Clinical Aspects (G Prodi, LA Liotta, PL Lollini, S Garbisa, S Gorini, K Hellmann, Eds.), pp. 351-360, Plenum Press, New York, (1987).
86) Alessio E, Attia W, Calligaris M, Cauci S, Dolzani L, Mestroni G, Monti-Bragadin C, Nardin G, Quadrifoglio F, Sava G, Tamaro M, Zorzet S. Metal complexes of platinum group: the promising antitumor features of cis-dichlorotetrakis-(dimethylsulfoxide) Ru(II) cis-RuCl2(Me2SO4) and related complexes. In: Platinum and other metal coordination compounds in cancer chemotherapy (Marino Nicolini Ed.), pp. 617-633, Martinus Nijhoff Publishing, Boston, (1988).
87) Sava G, Perissin L, Zorzet S. Antimetastatic action of orally administered lysozyme in mice bearing Lewis lung arcinoma. .Clin Expl. Metastasis., 6: 245-253 (1988). IF(1999)= 2.000
88) Sava G, Zorzet S, Perissin L, Giraldi T, Lassiani L. Effects of an inducer and an inhibitor of hepatic metabolism on the antitumor action of dimethyltriazenes. Cancer Chemother. Pharmacol., 21: 241-245 (1988). IF(1999)= 1.689
89) Ceschia V, Sava G, Gagliardi R, Zabucchi G. Effects of lysozyme on spleen and lungs in mice with Lewis lung carcinoma. Pharmacol. Res. Commun., 20: 615-616 (1988). IF(1999)= 0.715
90) Sava G, Ceschia V, Zabucchi G. Evidence for host-mediated antitumor effects of lysozyme in mice bearing MCa mammary carcinoma. Europ. J. Cancer Clin. Oncol., 24: 1737-1743 (1988). IF(1999)= 2.537
91) Alessio E, Mestroni G, Nardin G, Attia WM, Calligaris M, Sava G, Zorzet S. cis- and trans-dihalotetrakis(dimethylsulfoxide)ruthenium(II) complexes (RuX2(DMSO)4; X=Cl, Br): synthesis, structure and antitumor activity. Inorg. Chem., 27: 4099-4106 (1988). IF(1999)= 2.843
92) Giraldi T, Perissin L, Sava G, Zorzet S, Nicpali S, Rodani MG. Is effectiveness of cancer chemotherapy influenced by stress? In: Psicosomatica y Cancer (A Lobo, A Tres, Eds.), pp. 73-79, Ministero de Sanidad y Consumo, Madrid, (1988).
93) Sava G, Zorzet S, Pacor S, Mestroni G, Zassinovich G. Effects of two pyridinal-alkyliminerhodium(I) complexes in mice bearing MCa mammary carcinoma. Cancer Chemother. Pharmacol., 24: 302-306 (1989). IF(1999)= 1.689
94) Sava G, Pacor S, Ceschia V, Alessio E, Mestroni G. trans-Ru(II)dimethylsulphoxides: antineoplastic action on mouse tumors. Pharmacol. Res., 21: 453-454 (1989). IF(1999)= 0.715
95) Zorzet S, Perissin L, Piccini P, Rapozzi V, Pacor S, Sava G, Giraldi T. Tumour metastatic potential after treatment with selective antimetastatic drugs. Pharmacol. Res., 21: 457-459 (1989). IF(1999)= 0.715
96) Sava G, Pacor S, Ceschia V, Zassinovich G, Mestroni G. Inhibition of carrageenin paw edema by pyridinalalkylimine rhodium(I) complexes. Anticancer Res., 9: 767-770 (1989). IF(1999)= 1.375
97) Sava G, Pacor S, Ceschia V, Zassinovich G, Mestroni G. Antitumor effect of some rhodium(I) derivatives on MCa mammary carcinoma. Anticancer Res., 9: 787-790 (1989). IF(1999)= 1.375
98) Sava G, Benetti A, Ceschia V, Pacor S. Lysozyme and cancer: role of exogenous lysozyme as anticancer agent (review). Anticancer Res., 9: 583-592 (1989). IF(1999)= 1.375
99) Mestroni G, Alessio E, Calligaris M, Attia WM, Quadrifoglio F, Cauci S, Sava G, Zorzet S, Pacor S, Monti-Bragadin C, Tamaro M, Dolzani L. Chemical, biological and antitumor properties of ruthenium(II) complexes with dimethylsulfoxide. In: Progress in Clinical Biochemistry and Medicine, pp. 71-87, Springer-Verlag, Berlin, (1989).
100) Sava G, Pacor S, Zorzet S, Alessio E, Mestroni G. Antitumour properties of dimethylsulphoxide ruthenium(II) complexes in the Lewis lung carcinoma system. Pharmacol. Res., 21: 617-628 (1989). IF(1999)= 0.715
101) Sava G, Perissin L, Zorset S, Piccini P, Giraldi T. Antimetastatic action of the prostacyclin analog Iloprost in the mouse. Clin. Expl. Metastasis, 7: 671-678 (1989). IF(1999)= 2.000
102) Sava G, Ceschia V, Pacor S. Mechanism of the antineoplastic action of lysozyme: evidence for host mediated effects. Anticancer Res., 9: 1175-1180 (1989). IF(1999)= 1.375
103) Sava G. Reduction of B16 melanoma metastases by oral administration of egg-white lysozyme. Cancer Chemother. Pharmacol., 25: 221-222 (1989). IF(1999)= 1.689
104) Sava G, Ceschia V, Pacor S, Zorzet S, Perissin L. Antineoplastic action of egg-white lysozyme on the growth of MCa mammary carcinoma and TLX5 lymphoma in the CBA mouse. Meth. & Find. Exp. Clin. Pharmacol., 11: 683-689 (1989). IF(1999)= 0.454
105) Pacor S, Luxich E, Ceschia V, Sava G, Alessio E, Mestroni G. Effects of trans-RuCl2(DMSO)4 on B16 melanoma in mice. Pharmacol Res, 21 suppl 1: 127-128 (1989). IF(1999)= 0.715
106) Sava G, Pacor S, Bregant F, Ceschia V. Metal complexes of ruthenium in cancer chemotherapy. In: Metal Ions in Biology and Medicine (Ph Collery, LA Poirier, M Manfait, JC Etienne, Eds), pp. 471-475, John Libbey Eurotext, Paris, (1990).
107) Pacor S, Sava G, Bregant F, Ceschia V, Alessio E, Mestroni G. Antitumor action of mer-trichlorobis(dimethylsulphoxide)aminoruthenium(III) (BBR2382) in mice bearing Lewis lung carcinoma. In: Metal Ions in Biology and Medicine (Ph Collery, LA Poirier, M Manfait, JC Etienne, Eds), pp. 482-484, John Libbey Eurotext, Paris, (1990).
108) Sava G, Pacor S, Bregant F, Ceschia V, Luxich E, Alessio E, Mestroni G. Mechanism of tumor inhibition by the metal complex trans-RuCl2(dimethylsulphoxide)4. Pharmacol (Life Sci Adv), 9: 79-84 (1990).
109) Lassiani L, Eebert C, Nisi C, Varnavas A, Zorzet S, Sava G, Boccù E. Kinetic investigation of the aqueous stability and antitumor activity of a hydrosoluble diaryltriazene, AVIS, related to the antimetastatic agent DM-COOK. Pharmazie, 45: 743-745 (1990). IF(1999)= 0.446
110) Bregant F, Ceschia V, Pacor S, Sava G. Reduction of MCa mammary carcinoma in mice fed with egg-white lysozyme. Pharmacol. Res., 22, suppl.3: 95-96 (1990). IF(1999)= 0.715
111) Sava G, Pacor S, Bregant F, Ceschia V, Mestroni G. Metal complexes of ruthenium: antineoplastic properties and perspectives. Anti-Cancer Drugs, 1: 99-108 (1990). IF(1999)= 1.594
112) Vranesic B, Tomasic J, Kantoci D, Smerdel S, Sava G, Hrsak I. Novel bioactive adamantylpeptides. In: Peptides 1990 (E Giralt and D Andreu, Eds.), pp. 885-886, ESCOM Science Publishers B.V., (1990).
113) Sava G, Zorzet S, Perissin L, Pacor S, Lassiani L, Nisi C, VARNAVAS A. Antineoplastic action of p-(3-methyl-1-triazeno)benzoic acid potassium salt, a monomethyl derivative of the antimetastatic compound DM-COOK. Cancer Chemother. Pharmacol., 27: 423-428 (1991). IF(1999)= 1.689
114) Pacor S, Sava G, Ceschia V, Bregant F, Mestroni G, Alessio E. Antineoplastic effects of mer-trichlorobisdimethylsulphoxideaminorutheniumIII against murine tumors: comparison with cisplatin and with ImH[RuIm2Cl4]. Chem.-Biol. Interactions, 78: 223-234 (1991). IF(1999)= 1.887
115) Sava G, Ceschia V, Pacor S, Cartei F, Cartei G. Oral administration of lysozyme: preliminary results on the effects on T-lymphocyte subtypes of lymphocytopenic patients. J. Chemother. III -suppl. 3-: 133-136 (1991). IF(1999)= 0.770
116) Sava G, Pacor S, Bregant F, Ceschia V. Metal complexes of ruthenium: a potential class of selective anticancer drugs. Anticancer Res., 11: 1103-1108 (1991). IF(1999)= 1.375
117) Sava G, Ceschia V, Pacor S, Zabucchi G. Observations on the antimetastatic action of lysozyme in mice bearing Lewis lung carcinoma. Anticancer Res., 11: 1109-1114 (1991). IF(1999)= 1.375
118) Varnavas A, Nisi C, Lassiani L, Sava G, Perissin L, Boccù E. Synthesis and antitumor activity of hydrosoluble analogs of p-(3,3-dimethyl-1-triazeno)benzoic acid potassium salt. Arzneim.-Forsch./Drug Res., 41: 1168-1172 (1991). IF(1999)= 0.597
119) Cartei F, Cartei G, Ceschia V, Pacor S, Sava G. Hematologic effects of oral treatment with lysozyme chloride: a phase-II study. Curr. Ther. Res., 50: 530-538 (1991). IF(1999)= 0.651
120) Cartei F, Cartei G, Ceschia V, Pacor S, Sava G. Recovery of lymphocyte CD4+:CD8+ ratio in patients treated with lysozyme. Drug Invest., 4: 51-57 (1992).
121) Sava G, Pacor S, Mestroni G, Alessio E. Effects of the Ru(III) complexes [mer-RuCl3(DMSO)2Im]° and Na[trans-RuCl4(DMSO)Im] on solid mouse tumors. Anti-cancer Drugs, 3: 25-31 (1992). IF(1999)= 1.594
122) Pacor S, Sava G, Mestroni G, Alessio E. Tumor inhibition and effects on host survival time by RutheniumIII and RhodiumIII complexes with dimethylsulphoxide ligands. Pharmacol. Res. 25, suppl. 1: 73-74 (1992). IF(1999)= 0.715
123) Sava G, Pacor S, Mestroni G, Alessio E. Na[trans-RuCl4(DMSO)Im], a metal complex of ruthenium with antimetastatic properties. Clin. Exp. Metastasis, 10: 273-280 (1992). IF(1999)= 2.000
124) Sava G, Pacor S, Nardon E, Dobrina A. Effects of endotoxin in mice bearing solid metastasizing tumors and treated with lysozyme hydrochloride. J. Chemother., 4: 228-234 (1992). IF(1999)= 0.770
125) Sava G, Pacor S, Vranesic B, Tomasic J, Cocchietto M. Modification of growth of MCa mammary carcinoma of CBA mouse by new adamantylpeptides. Int. J. Oncology, 2: 607-612 (1993). IF(1999)= 1.381
126) Mestroni G, Alessio E, Sava G, Pacor S, Coluccia M. The development of tumor-inhibiting ruthenium dimethylsulfoxide complexes. In: Metal Complexes in Cancer Chemotherapy (BK Keppler Ed.), pp. 157-185, VCH, Weinheim, 1993.
127) Bregant F, Pacor S, Ghosh S, Chattopadyay SK, Sava G. Effects of some ruthenium chelates on MCa mammary carcinoma and on TLX5 lymphoma in mice. Anticancer Res., 13: 1007-1010, 1993. IF(1999)= 1.375
128) Coluccia M, Sava G, Loseto F, Nassi A, Boccarelli A, Giordano D, Alessio E, Mestroni G. Anti-leukaemic action of RuCl2(DMSO)4 isomers and prevention of brain involvement on P388 leukaemia and on P388/DDP subline. Eur. J. Cancer, 29A: 1873-1879, 1993. IF(1999)= 2.537
129) Sava G, Pacor S, Alessio E, Mestroni G, Gagliardi R, Cocchietto M, Coluccia M. Na[trans-RuCl4(DMSO)Im].2DMSO. Drugs of the Future, 18: 894-900, 1993.
130) Cartei G, Sava G, Salerno G, Sala PG, Vigevani E, Ceschia V, Clocchiatti L, Tabaro G. Synthetic thymic fraction 5: 24 hours high dose administration and circulating lymphocytes in immunodepressed patients. Preliminary results. In: Advances in management of malignancies (A Carpi, A Sagripanti, B Grassi Eds.), pp 245-246, Editoriale Bios s.a.s., Pisa, Italy, 1993.
131) Mestroni G, Alessio E, Sava G, Pacor S, Coluccia M, Boccarelli A. Water-soluble ruthenium(III)-dimethyl-sulfoxide complexes: chemical behaviour and pharmacological properties. Metal Based Drugs, 1: 41-63 (1993).
132) Pacor S, Franz C, Gagliardi R, Sava G. Lysozyme induced recovery of the response to ConA on mononuclear cells harvested from mice bearing MCa mammary carcinoma. Int. J. Oncology, 4: 877-883 (1994). IF(1999)= 1.381
133) Gagliardi R, Sava G, Pacor S, Mestroni G, Alessio E. Antimetastatic action and toxicity on healthy tissues of Na[trans-RuCl4(DMSO)Im] in the mouse. Clin. Exp. Metastasis, 12: 93-100 (1994). IF(1999)= 2.000
134) Dasic G, Pacor S, Bergamo A, Salerno G, Vranesic B, Jukic R, Tomasic J, Sava G. Effects of L-(adamant-2-yl)glycyl-L-alanyl-D-isoglutamine on the antitumor action of cyclophosphamide, 5-FU, cisplatin and dacarbazine on advanced carcinomas of the mouse. Int. J. Oncology, 5: 275-284 (1994). IF(1999)= 1.381
135) Sava G, Pacor S, Coluccia M, Mariggiò M, Cocchietto M, Alessio E, Mestroni G. Response of MCa mammary carcinoma to cisplatin and to Na[trans-RuCl4(DMSO)Im]. Selective inhibition of spontaneous lung metastases by the ruthenium complex. Drug Invest., 8: 150-161 (1994).
136) Sava G. Ruthenium compounds in cancer therapy. In: Metal Compounds in Cancer Therapy (SP Fricker, ed.) pp. 65-91, Chapman & Hall, London (1994).
137) Sava G, Pacor S, Bergamo A, Cocchietto M, Mestroni G, Alessio E. Effects of ruthenium complexes on experimental tumors: irrelevance of cytotoxicity for metastasis inhibition. Chem.-Biol. Interact.., 95: 109-126 (1995). IF(1999)= 1.887
138) Coluccia M, Sava G, Salerno G, Bergamo A, Pacor S, Mestroni G, Alessio E. Efficacy of 5-FU combined to Na[trans-RuCl4(DMSO)Im], a novel selective antimetastatic agent, on the survival time of mice with P388 leukemia, P388/DDP subline and MCa mammary carcinoma. Metal Based Drugs, 2: 195-199 (1995).
139) Sava G, Pacor S, Dasic G, Bergamo A. Lysozyme stimulates lymphocyte response to ConA and IL-2 and potentiates 5-fluorouracil action on advanced carcinomas. Anticancer Res., 15: 1883-1888 (1995). IF(1999)= 1.375
140) Pacor S, Giacomello E, Bergamo A, Gagliardi R, Cocchietto M, Sava G. Cytofluorimetric analysis of gut-intraepitelial and mesenteric lymph node lymphocytes of tumour bearing mice fed with egg-white lysozyme. Anticancer Res., 16: 145-150 (1996). IF(1999)= 1.375
141) Sava G, Salerno G, Bergamo A, Cocchietto M, Gagliardi R, Alessio E, Mestroni G. Reduction of lung metastases by Na[trans-RuCl4(DMSO)Im] is not coupled with the induction of chemical xenogenization. Metal Based Drugs, 3: 67-73 (1996).
142) Cocchietto M, Salerno G, Mestroni E, Alessio E, Sava G. Determination of ruthenium by atomic absorption spectroscopy after treatment with Na[trans-RuCl4(DMSO)Im]. In: Metal Ions in Biology and Medicine (Collery P, Corbella J, Domingo JL, Etienne JC, Llobet JM, eds.) vol. 4, pp. 381-383, John Libbey Eurotext, Paris (1996).
143) Sava G. Pharmacological aspects and therapeutic applications of lysozymes. In: Lysozymes: Model Enzymes in Biochemistry and Biology (Jollès P, ed.), pp. 433-449, Birkhäuser Verlag, Basel (1996).
144) Cartei G, Sava G, Salerno G, Bergamo A, Cartei F, Sanzari M, Sala PG, Vigevani E, Tabaro G, Clocchiatti L. Synthetic thymic fraction 5: Effects of high dose administration on circulating lymphocytes in patients. Cancer Biother. and Radiopharm., 11: 105-111 (1996). IF(1999)= 0.837
145) Sava G, Capozzi I, Bergamo A, Gagliardi R, Cocchietto M, Masiero L, Onisto M, Alessio E, Mestroni G, Garbisa S. Down-regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an antimetastatic ruthenium complex. Int. J. Cancer, 68: 60-66 (1996). IF(1999)= 3.545
146) Pacor S, Giacomello E, Bergamo A, Clerici K, Zacchigna M, Boccù E, Sava G. Antimetastatic action and lymphocyte activation by the modified lysozyme mPEG-Lyso in mice with MCa mammary carcinoma. Anticancer Res., 16: 2559-2564 (1996). IF(1999)= 1.375
147) Abramic M, Sava G, Zubanovic M, L. Vitale. Protease inhibitor produced by Streptomyces toyocaensis with antimetastatic activity in mice. Period. Biol., 98: 353-360 (1996).
148) Rosati A, Clerici K, Bergamo A, Sava G. Identification and measurement of transferrin receptors in a T-cell lymphocyte population by a fluorescent ligand. Cell. Pharmacol., 3: 225-230 (1996).
149) Bergamo A, Cocchietto M, Capozzi I, Mestroni G, Alessio E, Sava G. Treatment of residual metastases with Na[trans-RuCl4(DMSO)Im] and ruthenium uptake by tumour cells. Anticancer Drugs, 7: 697-702 (1996). IF(1999)= 1.594
150) Sava G, Bergamo A, Capozzi I, Clerici K, Pacor S, Gagliardi R, Giacomello E, Zacchigna M, Di Luca G, Boccù E. Stimulation of GALT and activation of mesenteric lymph node lymphocytes by a modified lysozyme in CBA mice with MCa mammary carcinoma. J. Expl. Ther. Oncol., 1: 342-349 (1996).
151) Sava G, Bergamo A. Pharmacological control of solid tumour metastases by ruthenium complexes. Curr. Topics Pharmacol., 3: 207-216 (1997).
152) Alessio E, Mestroni G, Sava G, Bergamo A, Coluccia M, Messori L. Ruthenium-sulphoxide complexes with a specific antimetastatic activity. In: «Cytotoxic, mutagenic and Carcinogenic Potential of Heavy Metals Related to human Environment.» (ND Hadjiliadis Ed.), pp. 457-466, Kluwer Academic Publishers, Boston (1997).
153) Sava G, Gagliardi R, Pacor S. Modulation of host immunity by lysozymes active on GALT in mice carrying solid malignant tumours. Curr. Topics Pharmacol., 3: 239-245 (1997).
154) Capozzi I, Clerici K, Cocchietto M, Salerno G, Bergamo A, Sava G. Modification of cell cycle and viability of TLX5 lymphoma in vitro by sulphoxide-ruthenium compunds and cisplatin detected by flow cytometry. Chemico-Biological Interactions, 113: 51-64 (1998). IF(1999)= 1.887
155) Mestroni G, Alessio E, Sessanta O Santi A, Geremia S, Bergamo A, Sava G, Boccarelli A, Schettino A, Coluccia M. Rhodium(III) analogues of antitumour-active ruthenium(III) compounds: the crystal structure of [ImH][trans-RhCl4(Im)2] (Im= imidazole). Inorg. Chim. Acta, 273: 62-71 (1998). IF(1999)= 1.295
156) Sava G, Capozzi I, Clerici K, Gagliardi R, Alessio E, Mestroni G. Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex. Clin. Exp. Metastasis, 16: 371-379 (1998). IF(1999)= 2.000
157) Sava G, Gagliardi R, Cocchietto M, Clerici K, Capozzi I, Marrella M, Alessio E, Mestroni G, Milanino R. Comparison of the effects of the antimetastatic compound ImH[trans-RuCl4(DMSO)Im] (NAMI-A) on the arthritic rat and on MCa mammary carcinoma in mice. Pathol. Oncol. Res., 4: 30-36 (1998).
158) Pacor S, Gagliardi R, Magnarin M, Carotenuto ME, Zabucchi G, Sava G. Reduction of growth ability and tumorigenicity of IL-4 transfected TS/A adenocarcinoma line is mediated by increased adhesion molecule expression. Haematologica, 83 (meeting supplement): 22-23 (1998). IF(1999)= 2.074
159) Sava G, Clerici K, Capozzi I, Cocchietto M, Gagliardi R, Alessio E, Mestroni G, Perbellini A. Reduction of lung metastasis by ImH[trans-RuCl4(DMSO)Im]: mechanism of the selective action investigated on mouse tumors. Anti Cancer Drugs, 10: 129-138 (1999). IF(1999)= 1.594
160) Bergamo A, Gagliardi R, Scarcia V, Furlani A, Alessio E, Mestroni G, Sava G. In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin. J. Pharmacol. Expl. Ther., 289: 559-564 (1999). IF(1999)= 3.300
161) Sava G, Gagliardi R, Bergamo A, Alessio E, Mestroni G. Treatment of metastases of solid mouse tumours by NAMI-A: comparison with cisplatin, cyclophosphamide and dacarbazine. Anticancer Res., 19: 969-972 (1999). IF(1999)= 1.375
162) Sava G, Bergamo A. Drug control of solid tumour metastases: a critical view. Anticancer Res., 19: 1117-1124 (1999). IF(1999)= 1.375
163) Sava G, Alessio E, Bergamo A, Mestroni G. Sulphoxide ruthenium complexes: non-toxic tools for the selective treatment of solid tumour metastases. In: Topics in Biological Inorganic Chemistry - Metallopharmaceuticals I (MJ Clarke, PJ Sadler Eds.), pp.143-169, Springer, Berlin (1999).
164) Pacor S, Gagliardi R, Spessotto P, Zabucchi G, Sava G. Paracrine effects of IL-4 transfection on TS/A adenocarcinoma cells mediate reduced in vivo growth. Pathol. Oncol. Res., 5: 110-116 (1999).
165) Callerio C, Gagliardi R, Sava G. Amplificazione della replicazione batteriofagica con batteri in fase stazionaria. Boll. Soc. Adriat. Sci, LXXVIII: 35-38, 1999.
166) Pacor S, Gagliardi R, Di Daniel E, Vadori M, Sava G. In vitro down regulation of ICAM-1 and E-cadherin and in vivo reduction of lung metastases of TS/A adenocarcinoma by a lysozyme derivative. Int. J. Mol. Med., 4: 369-375 (1999). IF(1999)= 1.058
167) Pacor S, Magnarin M, Carotenuto ME, Spessotto P, Zabucchi G, Sava G. In vitro growth of TS/A adenocarcinoma and of the gene transfected TS/A-IL4 line on biological substrates. Anticancer Res., 20: 191-196 (2000). IF(1999)= 1.375
168) Cocchietto M, Salerno G, Alessio E, Mestroni G, Sava G. Fate of the antimetastatic ruthenium complex ImH[trans-RuCl4(DMSO)Im] after acute i.v. treatment in mice. Anticancer Res., 20: 197-202 (2000). IF(1999)= 1.375
169) Sava G, Bergamo A. Ruthenium-based compounds and tumour growth control (Review). Int. J. Oncol., 17: 353-365, 2000. IF(1999)= 1.381
170) Magnarin M, Bergamo A, Carotenuto ME, Zorzet S, Sava G. Increase of tumour infiltrating lymphocytes in mice treated with antimetastatic doses of NAMI-A. Anticancer Res., 20: 2939-2944, 2000. IF(1999)= 1.375
171) Alessio E, Iengo E, Zorzet S, Bergamo A, Coluccia M, Boccarelli A, Sava G. Antimetastatic properties and DNA interactions of the novel class of dimeric Ru(III) compounds Na2[[(trans-RuCl4(Me2SO)]2(mu-L)] (L= ditopic, non-chelating aromatic N-ligand). A preliminary investigation. J. Inorg. Biochem., 79: 173-177, 2000. IF(1999)= 1.463
172) Zorzet S, Bergamo A, Cocchietto M, Sorc A, Gava B, Alessio E, Iengo E, Sava G. Lack of in vitro cytotoxicity, associated to increased G2-M cell fraction and inhibition of matrigel invasion, may predict in vivo selective antimetastasis activity of ruthenium complexes. J. Pharmacol. Expl. Ther., 295: 927-933, 2000. IF(1999)= 3.300
173) Cocchietto M, Sava G. Blood concentration and toxicity of the antimetastasis agent NAMI-A following repeated intravenous treatment in mice. Pharmacol. Toxicol., 87: 193-197, 2000. IF(1999)= 1.263
174) Sava G, Cocchietto M. Blood levels of ruthenium following repeated treatments with the antimetastatic compound NAMI-A in healthy Beagle dogs. In Vivo, 14: 741-744, 2000. IF(1999)= 0.794
175) Bergamo A, Zorzet S, Gava B, Sorc A, Alessio E, Iengo E, Sava G. Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells. Anti-Cancer Drugs, 11: 667-672, 2000. IF(1999)= 1.594
176) Zorzet S, Sorc A, Casarsa C, Cocchietto M, Sava G. Pharmacological effects of the ruthenium complex NAMI-A given orally to CBA mice with MCa mammary carcinoma. Metal Based Drugs, 8: 1-7, 2001.
177) Pacor S, Bacac M, Vadori M, Vismara D, Manfrin A, Sava G. Immunostimulating effects of oral lysozyme on a vaccination treatment with Vibrio anguillarum. Far. Ter., XVIII: 51-55, 2001.
178) Crul M, van den Bongard HJGD, Tibben MM, van Tellingen O, Sava G, Schellens JHM, Beijnen JH. Validated method for the determination of the novel organo-ruthenium anticancer drug NAMI-A in human biological fluids by Zeeman atomic absorption spectroscopy. Fresenius J. Anal. Chem., 369: 442-445, 2001.
179) Bergamo A, Zorzet S, Cocchietto M, Carotenuto ME, Magnarin M, Sava G. Tumour cell uptake, G2-M accumulation and cytotoxicity of NAMI-A on TS/A adenocarcinoma cells. Anticancer Res., 21: 1893-1898, 2001.
180) Pacor S, Vadori M, Vita F, Bacac M, Soranzo MR, Zabucchi G, Sava G. Isolation of a murine metastatic cell line and preliminary test of sensitivity to the antimetastasis agent NAMI-A. Anticancer Res., 21: 2523-2530, 2001.
181) Sava G, Bergamo A, Zorzet S, Gava B, Casarsa C, Cocchietto M, Furlani A, Scarcia V, Serli B, Iengo E, Alessio E, Mestroni G. Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A. Eur. J. Cancer, 38: 427-435, 2002.
182) Cocchietto M, Skert N, Nimis PL, Sava G. A review on usnic acid, an interesting natural compound. Naturwissenschaften, 89: 137-146, 2002.
183) Vacca A, Bruno M, Boccarelli A, Coluccia M, Ribatti D, Bergamo A, Garbisa S, Sartor L, Sava G. Inhibition of endothelial cell functions and angiogenesis by the metastasis inhibitor NAMI-A. Brit. J. Cancer, 86: 993-998, 2002.
184) Rossin R, Zorzet S, Zanella A, Turrin C, Sava G, Moschini G, Perbellini A, Mazzi U. In vivo biodistribution studies of hyaluronan butyrate by means of 99mTc direct labelling and YAP camera. In: Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine – 6 (M. Nicolini and U. Mazzi, eds.), pp. 689-693, SGEditoriali, Padova, 2002.
185) Pacor S, Giangaspero A, Bacac M, Sava G, Tossi A. Analysis of the cytotoxicity of synthetic antimicrobial peptides on mouse leukocytes: implications for systemic use. J. Antimicrob. Chemother., 50: 339-348, 2002.
186) Sanna B, Debidda M, Pintus G, Tadolini B, Posadino AM, Bennardini F, Sava G, Ventura C. The antimetastatic agent imidazolium trans-imidazoletetrachlororuthenate induces endothelial cell apoptosis by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase signaling pathway. Arch. Biochem. Biophys., 403: 209-218, 2002.
187) Bouma M, Nuijen B, Jansen MT, Sava G, Flaibani A, Bult A, Beijnen JH. A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A. Int. J. Pharm., 248: 239-246, 2002.
188) Bouma M, Nuijen B, Sava G, Perbellini A, Flaibani A, van Steenbergen MJ, Talsma H, Ketten-van den Bosch JJ, Bult A, Beijnen JH. Pharmaceutical development of a parental lyophilized formulation of the antimetastatic ruthenium complex NAMI-A. Int. J. Pharm., 248: 247-259, 2002.
189) Bouma M, Nuijen B, Jansen MT, Sava G, Bult A, Beijnen JH. Photostability profiles of the experimental antimetastatic ruthenium complex NAMI-A. J. Pharm. Biomed. Anal., 30: 1287-1296, 2002.
190) Frausin F, Cocchietto M, Bergamo A, Scarcia V, Furlani A, Sava G. Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells. Cancer Chemother. Pharmacol., 50: 405-411, 2002.
191) Bergamo A, Gava B, Alessio E, Mestroni G, Serli B, Cocchietto M, Zorzet S, Sava G. Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity. Int. J. Oncol., 21: 1331-1338, 2002.
192) Pintus G, Tadolini B, Posadino AM, Sanna B, Debidda M, Bennardini F, Sava G, Ventura C. Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A down regulates c-myc gene expression and endothelial cell proliferation. Eur. J. Biochem., 269: 5861-5870, 2002.
193) Akbayeva DN, Gonsalvi L, Oberhauser W, Peruzzini M, Vizza F, Brugeller P, Romerosa A, Sava G, Bergamo A. Synthesis, catalytic properties and biological activity of new water soluble ruthenium cyclopentadienyl PTA complexes [(C5R5)RuCl(PTA)2] (R= H, Me; PTA= 1,3,5-triaza-7-phosphaadamantane). Chem. Commun., 264-265, 2003.
194) Bouma M, Nuijen B, Jansen MT, Sava G, Picotti F, Flaibani A, Bult A, Beijnen JH. Development of a LC method for pharmaceutical quality control of the antimetastatic ruthenium complex NAMI-A. J. Pharm. Biomed. Anal. 31: 215-28, 2003
195) Cocchietto M, Zorzet S, Sorc A, Sava G. Primary tumor, lung and kidney retention and antimetastasis effect of NAMI-A following different routes of administration. Investigational New Drugs, 21: 55-62, 2003.
196) Bergamo A, Stocco G, Gava B, Cocchietto M, Alessio E, Serli B, Iengo E, Sava G. Distinct effects of dinuclear ruthenium(III) complexes on cell proliferation and on cell cycle regulation in human and murine tumor cell lines. J. Pharmacol. Exp. Ther., 305: 725-732, 2003.
197) Morbidelli L, Donnini S, Sava G, Messori L, Ziche M. Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers. FASEB JOURNAL 17 (5): A1370-A1370 Part 2 Suppl. S MAR 17, 2003
198) Morbidelli L, Donnini S, Filippi S, Messori L, Piccioli F, Orioli P, Sava G, Ziche M. Antiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers. Brit. J. Cancer, 88: 1481-1491, 2003.
199) Sava G, Zorzet S, Turrin C, Vita F, Soranzo MR, Cocchietto M, Bergamo A, DiGiovine S, Pezzoni G, Sartor L, Garbisa S. Dual action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen. Clin. Cancer Res., 9: 1898-1905, 2003.
200) Messori L, Marcon G, Orioli P, Fontani M, Zanello P, Bergamo A, Sava G, Mura P. Molecular structure, solution chemistry and biological properties of the novel [ImH][trans-IrCl(4)(Im)(DMSO)], (I) and of the orange form of [(DMSO)(2)H][trans-IrCl(4)(DMSO)(2)], (II), complexes. J. Inorg. Biochem., 95: 37-46, 2003.
201) Bergamo A, Messori L, Piccioli F, Cocchietto M, Sava G. Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferring. Invest New Drugs, 21: 401-11, 2003.
202) Bergamo A, Stocco G, Casarsa C, Cocchietto M, Alessio E, Serli B, Zorzet S, Sava G. Reduction of in vivo lung metastases by dinuclear ruthenium complexes is coupled to inhibition of in vitro tumour invasion. Int. J. Oncol., 24: 373-9, 2004.
203) Ferrari MB, Bisceglie F, Pelosi G, Tarasconi P, Albertini R, Dall'Aglio PP, Pinelli S, Bergamo A, Sava G. Synthesis, characterization and biological activity of copper complexes with pyridoxal thiosemicarbazone derivatives. X-ray crystal structure of three dimeric complexes. J. Inorg. Biochem., 98: 301-312, 2004.
204) Turel I, Pecanac M, Golobic A, Alessio E, Serli B, Bergamo A, Sava G. Solution, solid state and biological characterization of ruthenium(III)-DMSO complexes with purine base derivatives. J. Inorg. Biochem., 98: 393-401, 2004.
205) Bacac M, Hotze AC, Schilden K, Haasnoot JG, Pacor S, Alessio E, Sava G. Reedijk J. The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation. J. Inorg. Biochem., 98: 402-12, 2004.
206) Velders AH, Bergamo A, Alessio E, Zangrando E, Haasnoot JG, Casarsa C, Cocchietto M, Sava G. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)] and [mer-RuCl3(H20)(dmso-S)(dmtp= 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine). J. Med. Chem., 47: 1110-1121, 2004.
207) Bouma M, Nuijen B, Challa EE, Sava G. Flaibani A, Bult A, Beijnen JH. Stability and compatibility of the investigational antimetastatic ruthenium complex NAMI-A in infusion systems and its haemolytic potential. J. Oncol. Pharm. Practice, 10: 7-15, 2004.
208) Hotze AC, Caspers SE, De Vos D, Kooijman H, Spek AL, Flamigni A, Bacac M, Sava G. Haasnoot JG, Reedijk J. Structure-dependent in vitro cytotoxicity of the isomeric complexes [Ru(L)(2)Cl(2)] (L= o-tolylazopyridine and 4-methyl-2-phenylazopyridine) in comparison to [Ru(azpy)(2)Cl(2)]. J. Biol. Inorg. Chem., 9: 354-364, 2004.
209) Pacor S, Zorzet S, Cocchietto M, Bacac M, Vadori M, Turrin C, Gava B, Castellarin A, Sava G. Intra-tumoral nami-a treatment triggers metastasis reduction, which correlates to cd44 regulation and til recruitment. J Pharmacol Exp Ther., 310: 737-744, 2004.
210) Coradini D, Pellizzaro C, Abolafio G, Bosco M, Scarlata I, Cantoni S, Stucchi L, Zorzet S, Turrin C, Sava G, Perbellini A, Daidone MG. Hyaluronic-acid butyric esters as promising antineoplastic agents in human lung carcinoma: A preclinical study. Invest. New Drugs, 22: 207-217, 2004.
211) Ravera M, Baracco S, Cassino C, Colangelo D, Bagni G, Sava G, Osella D. Electrochemical measurements confirm the preferential bonding of the antimetastatic complex [ImH][RuCl(4)(DMSO)(Im)] (NAMI-A) with proteins and the weak interaction with nucleobases. J. Inorg. Biochem., 98: 984-90, 2004.
212) Sava G, Frausin F, Cocchietto M, Vita F, Podda E, Spessotto P, Furlani A, Scarcia V, Zabucchi G. Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A. Eur. J. Cancer, 40: 1383-1396, 2004.
213) Alessio E, Mestroni G, Bergamo A, Sava G. Ruthenium anticancer drugs. Met. Ions. Biol. Syst., 42: 323-351, 2004.
214) Bacac M, Vadori M, Sava G, Pacor S. Cocultures of metastatic and host immune cells: selective effects of NAMI-A for tumor cells. Cancer Immunol. Immunother., 53: 1101-1110, 2004.
215) Coradini D, Zorzet S, Rossin R, Scarlata I, Pellizzaro C, Turrin C, Bello M, Cantoni S, Speranza A, Sava G, Mazzi U, Perbellini A. Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clin. Cancer Res., 10: 4822-4830, 2004.
216) Margiotta N, Bergamo A, Sava G, Padovano G, De Clercq E, Natile G. Antiviral properties and cytotoxic activity of platinum(II) complexes with 1,10-phenanthrolines and acyclovir or penciclovir. J. Inorg. Biochem., 98: 1385-1390, 2004.
217) Casarsa C, Mischis MT, Sava G. TGFβ1 regulation and collagen-release-independent connective tissue re-modelling by the ruthenium complex NAMI-A in solid tumours. J. Inorg. Biochem., 98: 1648-1654, 2004.
218) Alessio E, Mestroni G, Bergamo A, Sava G. Ruthenium antimetastatic agents. Curr. Top. Med. Chem., 4:1525-1535, 2004.
219) Frausin F, Scarcia V, Cocchietto M, Furlani A, Serli B, Alessio E, Sava G. Free Exchange across cells, and echistatin-sensitive membrane target for the metastasis inhibitor NAMI-A (imidazolium trans-imidazole dimethyl sulfoxide tetrachlororuthenate) on KB tumor cells. J. Pharmacol. Exp. Ther., 313: 227-233, 2005.
220) Papadia P, Margiotta N, Bergamo A, Sava G, Natile G. Platinum(II) complexes with antitumoral/antiviral aromatic heterocycles: effect of glutathione upon in vitro cell growth inhibition. J. Med. Chem., 48:3364-3371, 2005.
221) Scolaro C, Bergamo A, Brescacin L, Delfino R, Cocchietto M, Laurenczy G, Geldbach TJ, Sava G, Dyson PJ. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. J. Med. Chem., 48:4161-4171, 2005.
222) Gava B, Zorzet S, Spessotto P, Cocchietto M, Sava G. Inhibition of B16 Melanoma Metastases with the Ruthenium Complex Imidazolium trans-Imidazoledimethylsulfoxide-tetrachlororuthenate and Down-Regulation of Tumor Cell Invasion. J. Pharmacol. Exp. Ther., 317:284-291, 2006.
223) Scolaro C, Geldbach TJ, Rochat S, Dorcier A, Gossens C, Bergamo A, Cocchietto M, Tavernelli I, Sava G, Rothlisberger U, Dyson PJ. Influence of Hydrogen-Bonding Substituents on the Cytotoxicity of RAPTA Compounds. Organometallics, 25:756-765, 2006.
224) Coradini D, Pellizzaro C, Scarlata I, Zorzet S, Garrovo C, Abolafio G, Speranza A, Fedeli M, Cantoni S, Sava G, Daidone MG, Perbellini A. A novel retinoic/butyric hyaluronan ester for the treatment of acute promyelocytic leukemia: preliminary preclinical results. Leukemia, 20:785-792, 2006.
225) Dyson PJ, Sava G. Metal-based antitumour drugs in the post genomic era. Dalton Trans., Apr. 28:1929-1933, 2006.
226) Khalaila I, Bergamo A, Bussy F, Sava G, Dyson PJ. The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy. Int. J. Oncol. 29:261-268, 2006.
227) Vock CA, Scolaro C, Phillips AD, Scopelliti R, Sava G, Dyson PJ. Synthesis, Characterization, and in Vitro Evaluation of Novel Ruthenium(II) eta(6)-Arene Imidazole Complexes. J. Med. Chem. 49:5552-5561, 2006.
228) Zorzin L, Cocchietto M, Voinovich D, Marcuzzi A, Filipovic-Grcic J, Mulloni C, Crembiale G, Casarsa C, Bulla R, Sava G. Lysozyme-containing chitosan-coated arginate microspheres for oral immunisation. J. Drug. Del. Sci. Tech., 16:413-420, 2006.
229) Bergamo A, Sava G. Ruthenium complexes can target determinants of tumour malignancy. Dalton Trans. Apr. 7:1267-1272, 2007.
230) Vock CA, Ang WH, Scolaro C, Phillips AD, Lagopoulos L, Juillerat-Jeanneret L, Sava G, Scopelliti R, Dyson PJ. Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms. J Med Chem. 50:2166-2175, 2007.
231) Griffith D, Bergamo A, Pin S, Vadori M, Muller-Bunz H, Sava G, Marmion CJ. Novel platinum pyridinehydroxamic acid complexes: synthesis, characterisation, X-ray crystallographic study and nitric oxide relaled properties. Polyhedron 26:4697-4706, 2007.
232) Scolaro C, Chaplin AB, Hartinger CG, Bergamo A, Cocchietto M, Keppler BK, Sava G, Dyson PJ. Tuning the hydrophobicity of ruthenium(ii)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy. Dalton Transactions. 14:5065-72, 2007.
233) Sava G. Metal based drugs restyled and resumed. Met. Based Drugs 2007:16260, 2007.
234) Bratsos I, Bergamo A, Sava G, Gianferrara T, Zangrando E, Alessio E. Influence of the anionic ligands on the anticancer activity of Ru(II)-dmso complexes: Kinetics of aquation and in vitro cytotoxicity of new dicarboxylate compounds in comparison with their chloride precursors. J Inorg Biochem. 102:606-617, 2008.
235) Griffith D, Cecco S, Zangrando E, Bergamo A, Sava G, Marmion CJ. Ruthenium(III) dimethyl sulfoxide pyridinehydroxamic acid complexes as potential antimetastatic agents: synthesis, characterisation and in vitro pharmacological evaluation. J Biol Inorg Chem. 13:511-520, 2008.
236) Bratsos I, Jedner S, Bergamo A, Sava G, Gianferrara T, Zangrando E, Alessio E. Half-sandwich Ru(II)[9]aneS(3) complexes structurally similar to antitumor-active organometallic piano-stool compounds: Preparation, structural characterization and in vitro cytotoxic activity. J Inorg Biochem. 102:1120-1133, 2008.
237) Pellizzaro C, Speranza A, Zorzet S, Crucil I, Sava G, Scarlata I, Cantoni S, Fedeli M, Coradini D. Inhibition of human pancreatic cell line MIA PaCa2 proliferation by HA-But, a hyaluronic butyric ester: a preliminary report. Pancreas 36:e15-23, 2008.
238) Cocchietto M, Zorzin L, Toffoli B, Candido R, Fabris B, Stebel M, Sava G. Orally administered microencapsulated lysozyme downregulates serum AGE and reduces the severity of early-stage diabetic nephropathy. Diabetes & Metab. 34:587-594, 2008.
239) Cocchietto M, Zorzin L, Veronesi PA, Sava G. Oral poly (ethylene glicol)-coniugated human recombinant lysozyme control of lung metastases in mice. Mol Med Rep. 1:847-850, 2008.
240) Bergamo A, Masi A, Dyson PJ, Sava G. Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound. Int J Oncol. 33:1281-1289, 2008.
241) Sava G, Bergamo A. Ruthenium drugs for cancer chemotherapy: an ongoing challenge to treat solid tumours. In: Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy, A. Bonetti et al. (eds), Humana Press. a part of Springer Science + Business Media. LLC 2009, pag: 57-66.
242) Bergamo A, Masi A, Jakupec MA, Keppler BK, Sava G. Inhibitory Effects of the Ruthenium Complex KP1019 in Models of Mammary Cancer Cell Migration and Invasion. Met Based Drugs 2009:681270. Epub 2009 Sep 17, 2009.
243) Bergamo A, Masi A, Peacock AF, Habtemariam A, Sadler PJ, Sava G. In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model. J Inorg Biochem. 2010 Jan;104(1):79-86.
244) Gianferrara T, Bergamo A, Bratsos I, Milani B, Spagnul C, Sava G, Alessio E. Ruthenium-porphyrin conjugates with cytotoxic and phototoxic antitumor activity. J Med Chem 2010, 53:4678-4690.
245) Mendes F, Groessl M, Nazarov AA, Tsybin YO, Sava G, Santos I, PJ Dyson, Casini A. Metal-based inhibition of poly(ADP-ribose) polymerase – the guardian angel of DNA. J Med Chem 2011, 54:2196-2206.
246) Ang WH, Casini A, Sava G, Dyson PJ. Organometallic ruthenium-based antitumor compounds with novel modes of action. Organomet Chem 2011, 696:989-998.
247) Bergamo A, Sava G. Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs. Dalton Trans 2011, 40:7817-7823.
248) Sava G, Bergamo A, Dyson PJ. Metal-based antitumour drugs in the post-genomic era: what comes next? Dalton Trans 2011, 40:9069-9075.
249) Quiroga AG, Ramos-Lima FJ, Alvarez-Valdés A, Font-BardíaM, Bergamo A, Sava G, Navarro-Ranninger C. Synthesis, characterization and tumor cell growth inhibition of new trans platinum complexes with phosphane derivatives. Polyhedron 2011, 30: 1646–1650
250) A. Bergamo, C. Gaiddon, J.H.M. Schellens, J.H. Beijnen, G. Sava. Approaching tumour therapy beyond platinum drugs. Status of the art and perspectives of ruthenium drug candidates. J Inorg Biochem 2012, 106:90-99.
251) Bergamo A, Delfino R, Casarsa C, Sava G. Hyperphosphorylation Maintenance Drives the Time-Course of G2-M Cell Cycle Arrest after Short Treatment with NAMI-A in KB Cells. Anti-Cancer Agents Med Chem 2012, 12:949-958.
252) Sava G, Jaouen G, Hillard EA, Bergamo A. Targeted Therapy vs. DNA-adduct formation-guided design: thoughts about the future of metal based anticancer drugs. Dalton Trans 2012 , 41:8226-8234.
253) M. Lucafò, S. Pacor, C. Fabbro, T. Da Ros, S. Zorzet, M. Prato, G. Sava. Study of a potential drug delivery system based on carbon nanoparticles: effects of fullerene derivatives in MCF7 mammary carcinoma cells. J Nanopart Res 2012, 14:1-13.
254) Santos RLSR, Bergamo A, Sava G, De Oliveira Silva D. Synthesis and characterization of a diruthenium(II,III)-ketoprofen compound and study of the in vitro effects on CRC cells in comparison to the naproxen and ibuprofen derivatives. Polyhedron, 2012, 42:175-181.
255) Vidimar V, Meng X, Klajner M, Licona C, Fetzer L, Harlepp S, Hébraud P, Sidhoum M, Sirlin C, Loeffler JP, Mellitzer G, Sava G, Pfeffer M, Gaiddon C. Induction of caspase 8 and reactive oxygen species by ruthenium-derived anticancer compounds with improved water solubility and cytotoxicity. Biochem Pharmacol 2012, 84:1428-1436.
256) Vadori M, Pacor S, Vita F, Zorzet S, Cocchietto M, Sava G. Features and full reversibility of the renal toxicity of the ruthenium-based drug NAMI-A in mice. J Inorg Biochem 2013, 118:21-27.
257) Cocchietto M, Blasi P, Lapasin P, Moro C, Gallo D, Sava G. Microencapsulation of Bioactive Principles with an Airless Spray-Gun Suitable for Processing High Viscous Solutions. J. Funct. Biomather. 2013, 4:312-328.
258) Lucafò M, Gerdol M, Pallavicini A, Pacor S, Zorzet S, Da Ros T, Prato M, Sava G. Profiling the molecular mechanism of fullerene cytotoxicity on tumor cells by RNA-seq. Toxicology 2013, 314:183-192.
259) Kumar SR, Lucafò M, Sava G, Nathanael AJ, Hong SI, Oh TH, Mangalaraj D, Viswanathan C, Popandian N. Hydrophilic polymer coated monodispersed Fe3O4 nanostructures and their cytotoxicity. Mat. Res. Express, 2014, 1:1-13
260) Gallo D, Cocchietto M, Masat E, Agostinis C, Harei E, Veronesi P, Sava G. Human recombinant lysozyme downregulates advanced glycan endproduct-induced interleukin-6 production and release in an in vitro model of human proximal tubular epithelial cells. Exp Biol Med (Maywood) 2014, 239:337-346.
261) Lucafò M, Pelillo C, Carini M, Da Ros T, Prato M, Sava G. A Cationic [60] Fullerene Derivative Reduces Invasion and Migration of HT-29 CRC Cells in Vitro at Dose Free of Significant Effects on Cell Survival. Micro-Nano Letters 2014, 6: 163-168.
262) Hudej R, Miklavcic D, Cemazar M, Todorovic V, Sersa G, Bergamo A, Sava G, Martincic A, Scancar J, Keppler BK, Turel I. Modulation of Activity of Known Cytotoxic Ruthenium(III) Compound (KP418) with Hampered Transmembrane Transport in Electrochemotherapy In Vitro and In Vivo. J Membr Biol 2015, 247: 1239-1251.
263) Bergamo A, Riedel T, Dyson PJ, Sava G. Preclinical combination therapy of the investigational drug NAMI-A with doxorubicin for mammary cancer. Invest New Drugs 2015, 33: 53-63.
264) Leijen S, Burgers SA, Baas, P, Pluim D, Tibben M, van Werkhoven E, Alessio E, Sava G, Beijnen JH, Schellens JH. Phase I/II study with ruthenium compound NAMI-A and gemcytabine in patients with non-small cell lung cancer after first line therapy. Invest New Drugs 2015, 33: 201-214.
265) Novohradsky V, Bergamo A, Cocchietto M, Zajac J, Brabec V, Mestroni G, Sava G. Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity. Dalton Transactions 2015, 44:1905-1913.
266) Bergamo A, Sava G. Linking the future of anticancer metal complexes to the therapy of tumour metastases. Chem Soc Rev 2015, 44:8818-8835.
267) Pelillo C, Bergamo A, Mollica H, Bestagno M, Sava G. Colorectal Cancer Metastases Settle in the Hepatic Microenvironment Through α5β1 Integrin. J Cell Biochem 2015, 116:2385-2396.
268) Vadori M, Florio C, Groppo B, Cocchietto M, Pacor S, Zorzet S, Candussio L, Sava G. The antimetastatic drug NAMI-A potentiates the phenylephrine-induced contraction of aortic smooth muscle cells and induces a transient increase in systolic blood pressure. J Biol Inorg Chem 2015, 20:831-840.
269) Pacor S, Grillo A, Đorđević L, Zorzet S, Lucafò M, Da Ros T, Prato M, Sava G. Effects of Two Fullerene Derivatives on Monocytes and Macrophages. BioMed Res International 2015, 2015:915130.
270) Bergamo A, Gerdol M, Lucafò M, Pelillo C, Battaglia M, Pallavicini A, Sava G. RNA-seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A. Metallomics 2015, 7:1439-1450.
271) Brescacin L, Masi L, Sava G, Bergamo A. Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process. J Biol Inorg Chem 2015, 7:1163-1173.
272) Gerdol M, Puillandre N, Moro GD, Guarnaccia C, Lucafò M, Benincasa M, Zlatev V, Manfrin C, Torboli V, Giulianini PG, Sava G, Venier P, Pallavicini A. Identification and characterization of a novel family of cysteine-rich peptides (MgCRP-I) from Mytilus galloprovincialis. Genome Biol evol 2015, 7:2203-2219.
273) Pelillo C, Mollica H, Eble JA, Grosche J, Herzog L, Codan B, Sava G, Bergamo A. Inhibition of adhesion, migration and of α5β1 integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A. J Inorg Biochem 2016, 160:225-235.
274) Castellarin A, Zorzet S, Bergamo A, Sava G. Pharmacological Activities of Ruthenium Complexes Related to Their NO Scavenging Properties. Int J Mol Sci 2016, pii: E1254. doi: 10.3390/ijms17081254
275) Manfrin C, Piazza F, Cocchietto M, Antcheva N, Masiello D, Franceschin A, Peruzza L, Bonzi LC, Mosco A, Guarnaccia C, Sava G, Giulianini PG. (2016). Can peptides be orally-delivered in crustaceans? The case study of the Crustacean Hyperglycaemic Hormone in Procambarus clarkii. AQUACULTURE, vol. 463, p. 209-216, ISSN: 0044-8486
276) Bergamo A, Pelillo C, Chambery A, Sava G. (2017). Influence of components of tumour microenvironment on the response of HCT-116 colorectal cancer to the ruthenium-based drug NAMI-A. J Inorg Biochem, 168:90-97. doi: 10.1016/j.jinorgbio.2016.11.031.
277) Lee RFS, Escrig S, Maclaclan C, Knott GW, Meibom A, Sava G, Dyson P. (2017). The differential distribution of RAPTA-T in non-invasive and invasive breast cancer cells correlates with its anti-invasive and anti-metastatic effects. Int J Mol Sci, 18, 1869; doi:10.3390/ijms18091869.
278) Bergamo A, Dyson PJ, Sava G. (2018). The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions. Coord Chem Rev, 360:17-33.
279) Bergamo A, Sava G. (2018). Chemical and Molecular Approach to Tumor Metastases. Int. J. Mol. Sci. 19, 843; doi:10.3390/ijms19030843.